Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity.

Solay, Asli Haykir; Acar, Ali; Eser, Fatma; Kuscu, Ferit; Tütüncü, Emin Ediz; Kul, Gülnur; Sentürk, Gönül Çiçek; Gürbüz, Yunus

Solay, Asli Haykir; Acar, Ali; Eser, Fatma; Kuscu, Ferit; Tütüncü, Emin Ediz; Kul, Gülnur; Sentürk, Gönül Çiçek; Gürbüz, Yunus.

Afiliação

Solay AH; Department of Infection Disease and Clinical Microbiology, Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Acar A; Department of Infection Disease and Clinical Microbiology, Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Eser F; Department of Infection Disease and Clinical Microbiology, Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Kuscu F; Department of Infection Disease and Clinical Microbiology, Çukurova University School of Medicine, Adana, Turkey.
Tütüncü EE; Department of Infection Disease and Clinical Microbiology, Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Kul G; Department of Infection Disease and Clinical Microbiology, Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Sentürk GÇ; Department of Infection Disease and Clinical Microbiology, Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
Gürbüz Y; Department of Infection Disease and Clinical Microbiology, Health Sciences University, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Turk J Gastroenterol ; 29(5): 561-565, 2018 09.

Article em En | MEDLINE | ID: mdl-30260778

Assuntos

Antirreumáticos/efeitos adversos; Fatores Biológicos/uso terapêutico; Vírus da Hepatite B/fisiologia; Hepatite B/virologia; Ustekinumab/efeitos adversos; Ativação Viral/efeitos dos fármacos; Adalimumab/efeitos adversos; Antivirais/uso terapêutico; Feminino; Hepatite B/tratamento farmacológico; Hepatite B/imunologia; Anticorpos Anti-Hepatite B/sangue; Humanos; Infliximab/efeitos adversos; Masculino; Pessoa de Meia-Idade; Estudos Retrospectivos; Fator de Necrose Tumoral alfa/antagonistas & inibidores

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativação Viral / Fatores Biológicos / Vírus da Hepatite B / Antirreumáticos / Ustekinumab / Hepatite B Tipo de estudo: Evaluation_studies / Observational_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google